6th Biotech Press-Lounge
Start-ups at the IZB are working in synchrony with medical progress
The pharmaceutical, biotech and venture capital scene met up in the Biotech Press-Lounge to incubate new projects. On October 12, 2017 the Innovation and Start-Up Center for Biotechnology (IZB) hosted the sixth Biotech Press-Lounge at the Faculty Club G2B (Gateway to Biotech). With over 100 guests attending the event, every last place was taken. In his opening speech, Dr. Peter Hanns Zobel, Managing Director of the Innovation and Start-up Center for Biotechnology (IZB), stressed how important it is to bring together the players in the pharmaceutical, biotech and venture capital scene in an informal atmosphere, and also that he was delighted with the financing acquired at the IZB in 2017. Pieris AG, Immunic AG and Rigontec GmbH alone brought in deals amounting to 2 billion Euros. Current research was presented within the context of impulse talks. This time speakers at the Biotech Press-Lounge were Dr. Markus Dangl (Senior Vice President of Research and Pre-Clinical Development at Medigene AG), PhD. Paola Casarosa (Corporate Vice President of Therapeutics at Boehringer Ingelheim) and Dr. Jens Altrichter (COO of Leukocare AG). Evelyn Warner, chief editor of the portal Labiotech.eu, moderated the event.
Dr. Markus Dangl, Senior Vice President of Research and Pre-Clinical Development at Medigene AG, reported why neoantigens are currently a very exciting topic in the field of immunotherapy of tumor diseases, and how the technologies and know-how of Medigene can be used in the future to treat patients using highly effective, individualized cell therapies.
“Partnerships play a strategic role in our research and development activities,” said PhD. Paola Casarosa, Corporate Vice President of Therapeutics at Boehringer Ingelheim in her talk. “This is illustrated by the fact that 50 percent of our pipeline is based on external collaborations. We are looking for partnerships across the entire spectrum, from universities to biotech companies, to deliver value to patients,” Casarosa explained.
Dr. Jens Altrichter, COO of Leukocare AG, outlined the increasing importance of advanced formulations in biopharmaceutical product development. “By taking into account formulation-relevant aspects already in the early phases of the development process, and using Leukocare’s expertise and technology platform, our customers can achieve significant competitive advantages to exploit the maximum product and market potential in the future,” as Altrichter explained the company’s strategy.